SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-000230
Filing Date
2023-01-05
Accepted
2023-01-05 16:12:48
Documents
13
Period of Report
2023-01-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-20230104.htm   iXBRL 8-K 60630
2 EX-99.1 kalv-ex99_1.htm EX-99.1 16722
  Complete submission text file 0000950170-23-000230.txt   199494

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20230104_lab.xml EX-101.LAB 13360
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20230104.xsd EX-101.SCH 2469
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20230104_pre.xml EX-101.PRE 9843
7 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20230104_htm.xml XML 4718
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 23511428
SIC: 2834 Pharmaceutical Preparations